新药申请-话题@MedSci

#新药申请#

77篇内容 | 2468人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1744165, encodeId=b3911e441653a, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=武田提交糖尿病新药trelagliptin新药申请, objectType=article, longId=31741, objectId=880231e41f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=880231e41f4, replyNumber=0, likeNumber=64, createdTime=2014-05-27, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=880231e41f4, moduleTitle=武田提交糖尿病新药trelagliptin新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=880231e41f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744163, encodeId=81fa1e4416398, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=武田在日本提交TAK-438新药申请, objectType=article, longId=31514, objectId=b9643151436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9643151436, replyNumber=0, likeNumber=61, createdTime=2014-04-14, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9643151436, moduleTitle=武田在日本提交TAK-438新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9643151436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744161, encodeId=51801e44161d1, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=吉利德提交丙肝新药Ledipasvir/Sofosbuvir新药申请, objectType=article, longId=30574, objectId=48d9305e40e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48d9305e40e, replyNumber=0, likeNumber=76, createdTime=2014-08-07, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48d9305e40e, moduleTitle=吉利德提交丙肝新药Ledipasvir/Sofosbuvir新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48d9305e40e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744160, encodeId=1ec91e44160ce, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=武田在日本提交甲吡唑新药申请, objectType=article, longId=28636, objectId=6daa28636b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6daa28636b6, replyNumber=0, likeNumber=57, createdTime=2014-12-06, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6daa28636b6, moduleTitle=武田在日本提交甲吡唑新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6daa28636b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744156, encodeId=d7fe1e44156bb, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=百时美在日本提交HCV全口服方案新药申请, objectType=article, longId=26221, objectId=84af2622184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84af2622184, replyNumber=0, likeNumber=71, createdTime=2014-05-22, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84af2622184, moduleTitle=百时美在日本提交HCV全口服方案新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84af2622184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744162, encodeId=6c321e44162d5, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=GSK提交药物Promacta的补充新药申请, objectType=article, longId=31462, objectId=2461314629f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2461314629f, replyNumber=0, likeNumber=98, createdTime=2014-10-04, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2461314629f, moduleTitle=GSK提交药物Promacta的补充新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2461314629f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744159, encodeId=6fbe1e4415922, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=QRxPharma公司向FDA再次提交Moxduo新药申请, objectType=article, longId=28178, objectId=1894281e805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1894281e805, replyNumber=0, likeNumber=63, createdTime=2014-05-30, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1894281e805, moduleTitle=QRxPharma公司向FDA再次提交Moxduo新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1894281e805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744158, encodeId=e7281e441587f, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=辉瑞Xeljanz补充新药申请（sNDA）获FDA批准, objectType=article, longId=26823, objectId=49fb26823e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49fb26823e2, replyNumber=0, likeNumber=56, createdTime=2014-04-20, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49fb26823e2, moduleTitle=辉瑞Xeljanz补充新药申请（sNDA）获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49fb26823e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744157, encodeId=bcef1e44157b7, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA接受阿斯利康naloxegol新药申请, objectType=article, longId=26820, objectId=98cb268203c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98cb268203c, replyNumber=0, likeNumber=65, createdTime=2013-12-18, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98cb268203c, moduleTitle=FDA接受阿斯利康naloxegol新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98cb268203c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744164, encodeId=d56b1e4416465, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请, objectType=article, longId=31581, objectId=e44e31581e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44e31581e0, replyNumber=0, likeNumber=68, createdTime=2014-11-06, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44e31581e0, moduleTitle=Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44e31581e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744155, encodeId=21621e441550f, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=葛兰素史克向FDA提交FF单药疗法新药申请, objectType=article, longId=25823, objectId=da872582317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da872582317, replyNumber=0, likeNumber=65, createdTime=2014-09-28, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da872582317, moduleTitle=葛兰素史克向FDA提交FF单药疗法新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da872582317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744154, encodeId=db0c1e44154f7, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请（sNDA）, objectType=article, longId=21572, objectId=b9d4215e217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d4215e217, replyNumber=0, likeNumber=55, createdTime=2014-05-15, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d4215e217, moduleTitle=FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请（sNDA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9d4215e217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744153, encodeId=90471e44153c6, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=大冢及Lundbeck长效版Abilify新药申请审批遭FDA推迟, objectType=article, longId=8436, objectId=788e843634, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788e843634, replyNumber=0, likeNumber=109, createdTime=2012-08-16, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788e843634, moduleTitle=大冢及Lundbeck长效版Abilify新药申请审批遭FDA推迟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788e843634)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744150, encodeId=abff1e44150e2, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=Gabapentin口服液仿制药新药申请获得美FDA批准, objectType=article, longId=5994, objectId=9aeb59945c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aeb59945c, replyNumber=0, likeNumber=82, createdTime=2013-04-09, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aeb59945c, moduleTitle=Gabapentin口服液仿制药新药申请获得美FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aeb59945c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744152, encodeId=75741e4415295, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=XenoPort向FDA提交XP23829研究性新药申请, objectType=article, longId=6667, objectId=7c23666e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c23666e3b, replyNumber=0, likeNumber=101, createdTime=2012-12-06, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c23666e3b, moduleTitle=XenoPort向FDA提交XP23829研究性新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c23666e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744151, encodeId=4cea1e44151b2, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=Medivation与Astellas提交前列腺癌药物enzalutamide新药申请, objectType=article, longId=6483, objectId=b67e648371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b67e648371, replyNumber=0, likeNumber=110, createdTime=2012-11-11, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b67e648371, moduleTitle=Medivation与Astellas提交前列腺癌药物enzalutamide新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b67e648371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1744149, encodeId=733f1e44149a3, content=<a href='/topic/show?id=657a58646ca' target=_blank style='color:#2F92EE;'>#新药申请#</a>, objectTitle=健赞及Isis公司宣布提交HoFH药物KYNAMRO新药申请, objectType=article, longId=5406, objectId=f99d540607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f99d540607, replyNumber=0, likeNumber=74, createdTime=2013-03-27, rootId=0, userName=wangbingxhy, userId=ab3c35313981, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f99d540607, moduleTitle=健赞及Isis公司宣布提交HoFH药物KYNAMRO新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f99d540607)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新药申请

2020-05-29

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

武田提交糖尿病新药trelagliptin新药申请

2014-05-27

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

武田在日本提交TAK-438新药申请

2014-04-14

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

吉利德提交丙肝新药Ledipasvir/Sofosbuvir新药申请

2014-08-07

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

武田在日本提交甲吡唑新药申请

2014-12-06

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

百时美在日本提交HCV全口服方案新药申请

2014-05-22

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

GSK提交药物Promacta的补充新药申请

2014-10-04

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

QRxPharma公司向FDA再次提交Moxduo新药申请

2014-05-30

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

辉瑞Xeljanz补充新药申请（sNDA）获FDA批准

2014-04-20

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA接受阿斯利康naloxegol新药申请

2013-12-18

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请

2014-11-06

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

葛兰素史克向FDA提交FF单药疗法新药申请

2014-09-28

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请（sNDA）

2014-05-15

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

大冢及Lundbeck长效版Abilify新药申请审批遭FDA推迟

2012-08-16

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

Gabapentin口服液仿制药新药申请获得美FDA批准

2013-04-09

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

XenoPort向FDA提交XP23829研究性新药申请

2012-12-06

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

Medivation与Astellas提交前列腺癌药物enzalutamide新药申请

2012-11-11

wangbingxhy (审核中...)

前往app查看评论内容

#新药申请#

健赞及Isis公司宣布提交HoFH药物KYNAMRO新药申请

2013-03-27

科室
- - 订阅+
  - 更多科室
工具
服务